$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 Class A ordinary shares at a purchase price of $2.00 per share in a registered ...

NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp. Dr. Philips is the co-founder, President, and Chief Executive Officer of Spheryx, Inc., a technology company developing holographic microscopic techniqu ...

| 代码 | 名称 | 最新价 | 涨跌幅√ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | UPC | 大自然药业 | 9.460 | 82.98% | +4.290 | 2.35亿 | | MSC | 新濠影汇 | 4.680 | 19.23% | +0.755 | 4.85万 | | IMAB | I-Mab | 5.070 | 16.02% | +0.700 | 2976.31万 | | APM | 知临集团 | 2.410 | 15.31% | +0.320 | 160.78万 | | CHNR | 中国天然资源 | 5.700 | 14.84% | +0.737 | 886.04万 | 中概股收盘涨幅前五的个股为：大自然药业涨82.98%，新濠影汇涨19.23%，I-Mab涨16.02%，知临集团 涨15.31%，中国天然资源涨14.84%。(格隆汇) ...

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconferen ...

Core Viewpoint - Chinese concept stocks experienced significant declines, with the top five losers showing steep drops in their stock prices, indicating potential market volatility and investor concerns [1] Group 1: Stock Performance - Dongfang Culture (OCG) saw a decline of 17.19%, closing at 2.890, with a trading volume of 585,300 [1] - Renkong Technology (RCON) dropped by 12.69%, ending at 2.270, with a trading volume of 1,132,700 [1] - Zhiling Group (APM) fell by 11.74%, closing at 2.330, with a trading volume of 6,809,100 [1] - Luda Technology (LUD) decreased by 10.66%, finishing at 5.280, with a trading volume of 75,800 [1] - Dingxin Holdings (DXST) experienced a drop of 10.31%, closing at 1.130, with a trading volume of 60,800 [1]

| 代码 | 名称 | 最新价 | 涨跌幅√ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | APM | 知临集团 | 4.250 | 234.65% | +2.980 | 12.82亿 | | LUD | 禄达技术 | 6.520 | 49.89% | +2.170 | 109.79万 | | DDC | 日日煮 | 13.450 | 28.83% | +3.010 | 286.97万 | | DKI | 黑瞳科技 | 4.500 | 24.14% | +0.875 | 131.55万 | | STAK | 斯塔克工业 | 1.730 | 20.98% | +0.300 | 455.84万 | 中概股收盘涨幅前五的个股为：知临集团涨234.65%，禄达技术涨49.89%，日日煮涨28.83%，黑瞳科技 涨24.14%，斯塔克工业涨20.98%。(格隆汇) ...

Aptorum Group Limited APM stock is trading higher on Thursday, with a robust session volume of 168.16 million compared to the average volume of 3.25 million, as per data from Benzinga Pro. Its merger partner, DiamiR Biosciences Corp., received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). Also Read: Thermo Fisher Positioned As Biopharma's Partner Of Choice This milestone allows DiamiR to offer its validated A ...

作者：行情君 资料显示，知临集团有限责任公司(Nasdaq:APM)是一家生物制药企业致力推进一系列崭新医疗及诊断 科技的研发和商品化以应对未被满足的医疗需求。知临集团当前的药品开发项目包括孤儿疾病,传染病 和代谢性疾病的适应症,其中一些项目目标于2020年进入临床试验阶段。知临集团还经营着一家女性保 健品业务,其DioscoreaOpposita生物活性营养片剂目前正在商业化。 本文源自：金融界 8月21日，知临集团(APM)开盘上涨123.62%，截至21:30，报2.84美元/股，成交2.53亿美元，总市值 2028.83万美元。 财务数据显示，截至2023年12月31日，知临集团收入总额43.14万美元，同比减少66.71%；归母净利 润-282.46万美元，同比增长71.18%。 ...

Core Viewpoint - DiamiR Biosciences Corp. has received approval for its APOE Genotyping test from the New York State Department of Health, allowing it to offer this test through its accredited laboratory, which is a significant milestone for the company in expanding its diagnostic capabilities for brain health [1][3][4] Company Overview - DiamiR Biosciences is focused on developing innovative blood-based diagnostic tests for brain health and other diseases, with a particular emphasis on neurodegenerative conditions [1][8] - The company utilizes a proprietary platform technology that analyzes microRNA signatures in plasma for early detection and monitoring of brain health conditions [8] Regulatory Approval - The approval from the New York State Department of Health is part of the Clinical Laboratory Evaluation Program (CLEP), which is known for its stringent validation standards for laboratory-developed tests [2][3] - This approval enables DiamiR to provide its APOE Genotyping test using various biological samples, including blood and saliva, through licensed healthcare providers [1][2] APOE Testing Significance - The APOE test identifies genetic variants linked to the risk of late-onset Alzheimer's disease, with the APOE ε4 allele being the strongest known genetic risk factor [4] - Individuals with one copy of the APOE ε4 allele have a 3-4 times higher risk of developing Alzheimer's, while those with two copies have an 8-12 times higher risk compared to non-carriers [4] Merger Announcement - DiamiR Biosciences and Aptorum Group Limited have entered into a definitive agreement for an all-stock merger, which is expected to close in the fourth quarter of 2025, subject to stockholder approval [6] - Upon completion of the merger, DiamiR will become a wholly-owned subsidiary of Aptorum Group [6] Broader Diagnostic Portfolio - DiamiR's diagnostic portfolio includes tests for monitoring brain health through the analysis of circulating brain-enriched and inflammation-associated microRNAs in blood plasma [5]

Core Points - Aptorum Group Limited has regained compliance with Nasdaq's minimum bid price requirement, confirming that its Class A ordinary shares closed at least $1.00 for 10 consecutive business days prior to the October 14, 2025 deadline [1][2][3] - The closing bid price was maintained at $1.00 or greater from July 16, 2025 to July 30, 2025, leading to the closure of the compliance matter by Nasdaq [2][3] - Aptorum Group announced an all-stock merger with DiamiR Biosciences, which will become a wholly-owned subsidiary upon completion of the transaction [4] Company Overview - Aptorum Group Limited is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology and infectious diseases [5] - DiamiR Biosciences specializes in developing minimally invasive tests for early detection and monitoring of brain health conditions and other diseases, utilizing a proprietary platform technology based on microRNA signatures [6]